Expanding Veterans’ Access to Emerging Treatments Act
Sponsored By: Representative Bergman
In Committee
Summary
This bill would create expanded VA research and access to innovative treatments for veterans. It would set up an investigational research program so veterans with conditions like PTSD, chronic pain, depression, anxiety, traumatic brain injury, or substance use disorders can join clinical trials or be considered for compassionate or extended access to emerging therapies such as MDMA, psilocybin, ketamine, ibogaine, and others.
Show full summary
- Veterans: Veterans diagnosed with covered conditions could participate in one or more VA clinical trials or seek compassionate or extended access to listed innovative treatments.
- VA operations and staff: The Secretary would have to name a lead administrator within 60 days and develop the program within 90 days. The VA may run clinical trials and may use amounts otherwise authorized to support them.
- Oversight and review: The Secretary must report within 1 year on hosting clinics, expected participant numbers, trial findings, and reviews of safety, efficacy, cost, regulatory, and logistical issues. The program must be reviewed at 2 years to decide whether to extend or end it.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More experimental treatment access for veterans
This bill would require the Department of Veterans Affairs to start an investigational research program within 90 days to study and, where appropriate, provide veterans access to innovative treatments and emerging therapies for listed conditions. The VA would have to name a lead administrator within 60 days and could run clinical trials that include veterans and create a compassionate or extended access process for care when clinically appropriate. The bill would list example innovative treatments such as MDMA, psilocybin, ketamine, ibogaine, and DMT, and it would require the VA to follow federal laws on investigational products and controlled substances. The VA would report to the House and Senate Veterans' Affairs committees within one year and review the program within two years; funding would be limited to amounts already authorized and available to the VA.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Bergman
MI • R
Cosponsors
Rep. Correa, J. Luis [D-CA-46]
CA • D
Sponsored 1/15/2026
Crenshaw
TX • R
Sponsored 2/11/2026
Rep. Luttrell, Morgan [R-TX-8]
TX • R
Sponsored 2/24/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in